 |
|
Finger's Amniotic Membrane Buffer TechniqueProtecting the Cornea During Radiation Plaque Therapy
Paul T. Finger, MD
Arch Ophthalmol. 2008;126(4):531-534.
ABSTRACT
Objective To use amniotic membranes as a buffer between the cornea and radioactive eye plaques.
Methods Six melanomas were treated with ophthalmic plaque radiation therapy. Plaque-tumor localization required that a portion of the gold plaque touch the cornea during treatment. To enhance patient comfort and protect the cornea, an (0.1-mm-thick) amniotic membrane was interposed between the metal plaque edge and the cornea.
Results Minimal ocular discomfort was noted during plaque radiation therapy. On a scale of 1 (none) to 10 (severe), all 6 patients reported pain levels of 1. As a tissue equivalent and because the mean thickness was only 0.1 mm, amniotic membranes had no significant effect on radiation dose calculations. No adverse effects, infections, or abrasions were noted.
Conclusion The amniotic membrane buffer technique improves patient comfort and protects the cornea during ophthalmic plaque radiation therapy.
INTRODUCTION
Radioactive plaque therapy has been used for the treatment of iris, iridociliary, and ciliary body malignant neoplasms.1-4 In this therapy, the surgeon must affix the plaque to cover the tumor's base plus a free margin of normal-appearing tissue; tumors that extend to the iris root or are in the iris require that the metal plaque edge rest on the cornea. In these cases, postoperative findings of corneal epithelial ridges and abrasions are common transient findings. Plaque-cornea touch (during treatment) is also uncomfortable and occasionally painful.
Amniotic membrane patching was introduced in ophthalmology to treat extreme chemical burns of the conjunctiva and cornea, to manage persistent corneal epithelial defects, and for reconstruction of the conjunctival fornices.5-11 The membranes are available as freeze-dried or frozen rectangles of tissue that have been placed, sewn, and glued on recipient sites. In this study, an amniotic membrane graft (AMG) was used to act as a buffer between the gold rim and the cornea during ophthalmic plaque radiation therapy.
METHODS
PATIENT SELECTION
This study conforms to the tenets of the Declaration of Helsinki and the Health Insurance Privacy and Accountability Act of 1996. Patients signed consent forms for the investigational use of AMGs, and approval was obtained from The New York Eye Cancer Center's Internal Review Board, New York.
Six patients with biopsy-proved anterior uveal melanoma were screened for metastatic disease and found suitable for ophthalmic plaque radiation therapy (Table 1). Each tumor involved the iris, the ciliary body, or both (iridociliary). Coverage of the entire tumor and a 2-mm tumorfree margin required that the gold plaque override and thereby contact the cornea.
|
|
|
|
Table 1. Characteristics of the 6 Study Patients With Melanomaa
|
|
|
TUMOR LOCALIZATION
Tumor localization and episcleral plaque insertion involved measuring the anterior margins as visible through the cornea, found to extend along the anterior chamber angle on gonioscopy and within the ciliary body (as revealed by high-frequency ultrasonography).12 The posterior tumor margins were also visible on transillumination or obscured by the ciliary body band. In such cases, the posterior margin of the ciliary body band was used as the posterior tumor margin. In all cases, the plaque was placed to cover the entire tumor plus a 2- to 3-mm tumor-free margin. This required that the plaques be placed on the corneal surface.
AMNIOTIC MEMBRANE BUFFER INSERTION
A 360° conjunctival peritomy was performed around the corneal scleral limbus. A curved Stevens scissors was used to open Tenon's capsule in all 4 quadrants. Depending on the tumor's shape, either a custom-made anterior segment plaque or a standard round plaque was sewn to the eye to cover the episcleral and epicorneal markings.
In this series, we used six 1 x 1.5-cm frozen AMGs (Bio-Tissue, Miami, Florida). The tissue used has been reported to be a mean of 0.1 mm thick.13 Each AMG was placed sticky-side up on the cornea (Figure 1). This approach typically required some gentle teasing of the AMG to become flattened on the corneal surface. While the assistant gently raises the posterior edge of the plaque, the surgeon slides the AMG beneath the gold plaque (Figure 1). The AMG should cover the affected cornea but not be folded beneath the plaque. Folding of the graft (beneath the plaque) should be avoided because it might cause significant plaque displacement (away from the tumor). Extra AMG can be left on the unaffected cornea (Figure 2). Last, the posterior aspect of the plaque was covered by the patient's conjunctiva to shield it from eyelid trauma. Once irradiation was completed, the conjunctiva was opened and the plaque and AMG were removed.
|
|
|
|
Figure 1. The steps used in Finger's amniotic membrane buffer technique to place the amniotic membrane graft (AMG) beneath the corneal portion of an epibulbar radiation eye plaque. A, The yellow gold plaque on the left with the AMG sticky-side up on the adjacent cornea. B, The plaque is slightly raised to accommodate sliding the AMG beneath its corneal surface (arrows). C, When the plaque is released, it secures the AMG in position (arrowheads).
|
|
|
|
|
|
|
Figure 2. Surgeon performing Finger's amniotic membrane buffer technique. A, The amniotic membrane graft (AMG) is seen as a gray translucent membrane (arrowheads) beneath the anterior corneal edges of a standard round gold radiation plaque. B, The AMG is seen as a gray translucent membrane (arrowheads) beneath the anterior corneal edges of a custom-designed gold plaque. Additional conjunctival flaps were sewn to cover the posterior aspect of the plaques.
|
|
|
RADIATION DOSIMETRY
Preoperative comparative dosimetry was performed on all patients before plaque insertion. Because of the availability of 2 low-energy radionuclides in our center, palladium Pd 103 (103Pd) was compared with iodine I 125 sources in gold plaques. As a result of these preoperative comparative dosimetry comparisons, all patients were treated with 103Pd (Table 2).
|
|
|
|
Table 2. Radiation Dosimetry of the Study Patients
|
|
|
The choice of 103Pd marginally increased the mean radiation dose to the subjacent sclera (4%) and lens (2%) and decreased the mean radiation dose to the patient's macula (foveal dose) by 48%. These numbers are important for several reasons. The scleral dose comparison revealed a slight (questionably significant) increase in irradiation of the tumor. The lens doses were both cataractogenic and relatively equivalent. In contrast, the macula was the farthest point measured from the plaque and most closely represents the total organ dose (that received by the eye as a whole). In this study, the eyes received up to 48% less radiation because of the use of 103Pd.14-15
The mean 0.1-mm thickness of the AMG and its potential effect on the tumor dose were not considered significant enough to include in our calculations. Like other discounted variables, AMG thickness is similar to the standard error of ultrasonography tumor measurements (0.1 mm) and the thickness of the retained conjunctiva at the limbus (also typically disregarded during dosimetric calculations). In addition, this thickness is at least partially compensated for by the 4% increase in base dose provided by the use of 103Pd (instead of iodine 125). In this study, patients were prescribed a mean dose of 83 Gy to the deepest measured point the tumor extended into the eye (Table 2).
PLAQUE RADIATION THERAPY
All patients received one 7-day plaque radiation course that started at insertion and continued until the prescribed dose was delivered to the point of deepest intraocular tumor extension (as measured by high-frequency ultrasonography after dilation). Continuous postoperative mydriasis and cycloplegia were prescribed to immobilize the tumor, minimize its size, and reduce the need for anterior plaque extension during radiation therapy. Postoperative topical antibiotic steroid eyedrops were also placed on the eye 4 times daily.
RESULTS
Amniotic membranes were placed between the cornea and epicorneal radioactive plaques in 6 patients (Figure 2). By the American Joint Committee on Cancer–International Union Against Cancer Criteria (AJCC-UICC) staging system, there was 1 T1a iris tumor (fewer than 3 clock hours), 4 T2 iridociliary tumors (confluent with or extending into the ciliary body and/or choroid), 1 T1c ciliary body tumor, and 1 T2 ciliary body tumor (>10 mm in largest basal dimension).16 Each was in contact with or extended anteriorly to the corneal scleral limbus, thus requiring anterior plaque placement (Table 1).
On the day after plaque insertion until the day before explantation surgery, patients were asked if they were experiencing eye pain. On a subjective scale from 1 (none) to 10 (severe), all 6 patients noted a pain level of 1 (Table 2). During that same interval, no patients required narcotic pain medication.
In no case did the amniotic membrane graft require an interruption of treatment. No infections, allergic reactions, or corneal abrasions occurred (during or after plaque radiation therapy). Amniotic membranes were totally and easily removed at the time of plaque explantation. No perioperative complications could be attributed to the use of the amniotic membrane buffer technique.
COMMENT
Iridectomy or iridocyclectomy had been the procedures of choice for select iris and ciliary body melanomas.17-19 However, ophthalmic plaque radiation therapy offers the advantages of larger treatment margins and retained iris function.2 In contrast to intraocular surgery, extraocular plaque radiation therapy carries little risk of hyphema, endophthalmitis, or retinal detachment.2, 4 Iris retention reduces postoperative symptoms of glare. Although the incidence of secondary radiation cataract is high, little maculopathy has been noted.14 In 2001, I published an article2 about the first use of ophthalmic plaque radiation therapy for resectable iris and iridociliary melanoma. Now widely used, plaque radiation therapy has been found to be both safe and effective for most anterior uveal tumors.4, 12, 20 However, many patients are uncomfortable and some experience significant pain when the plaque's edge rests on the cornea. Acute corneal findings can include temporary epithelial ridges and abrasions. No corneal infections, ulcerations, dystrophies, or opacities have been reported.2-4,12
E. Rand Simpson, MD (oral communication, August 2007), and others have described methods to enhance patient comfort during anterior plaque radiation therapy. These methods include full conjunctival cover techniques (as described in the "Methods" section), superior rectus muscle disengagement (for inferior plaque positions), and customized nonpressure dressings. Although these techniques address exposure of the anterior surface of the plaque (between the eyelids), my amniotic membrane buffer technique creates a buffer between the posterior surface of the plaque and the cornea. No short-term complications were noted, all patients were comfortable throughout treatment.
AUTHOR INFORMATION
Correspondence: Paul T. Finger, MD, The New York Eye Cancer Center, 115 E 61st St, New York, NY 10065 (pfinger{at}eyecancer.com).
Submitted for Publication: September 4, 2007; final revision received September 17, 2007; accepted September 17, 2007.
Financial Disclosure: None reported.
Funding/Support: This study was supported by The EyeCare Foundation Inc, New York, NY (http://eyecarefoundation.org).
Author Affiliation: The New York Eye Cancer Center, The New York Eye and Ear Infirmary, and the New York University School of Medicine, New York.
REFERENCES
| |
1. Finger PT. Radiation therapy for choroidal melanoma. Surv Ophthalmol. 1997;42(3):215-232.
FULL TEXT
|
ISI
| PUBMED
2. Finger PT. Plaque radiation therapy for malignant melanoma of the iris and ciliary body. Am J Ophthalmol. 2001;132(3):328-335.
FULL TEXT
|
ISI
| PUBMED
3. Marigo FA, Finger PT. Anterior segment tumors: current concepts and innovations. Surv Ophthalmol. 2003;48(6):569-593.
FULL TEXT
|
ISI
| PUBMED
4. Shields CL, Naseripour M, Shields JA, Freire J, Cater J. Custom-designed plaque radiotherapy for nonresectable iris melanoma in 38 patients: tumor control and ocular complications. Am J Ophthalmol. 2003;135(5):648-656.
FULL TEXT
|
ISI
| PUBMED
5. Kruse FE, Rohrschneider K, Völcker HE. Transplantation of amniotic membrane for reconstruction of the eye surface [in German]. Ophthalmologe. 1998;95(2):114-119.
FULL TEXT
|
ISI
| PUBMED
6. Ferreira De Souza R, Hofmann-Rummelt C, Kruse FE, Seitz B. Multilayer amniotic membrane transplantation for corneal ulcers not treatable by conventional therapy: a prospective study of the status of cornea and graft during follow-up [in German]. Klin Monatsbl Augenheilkd. 2001;218(8):528-534.
FULL TEXT
| PUBMED
7. Hanada K, Shimazaki J, Shimmura S, Tsubota K. Multilayered amniotic membrane transplantation for severe ulceration of the cornea and sclera. Am J Ophthalmol. 2001;131(3):324-331.
FULL TEXT
|
ISI
| PUBMED
8. Kasparov AA, Trufanov SV. Use of preserved amniotic membrane for reconstruction of the surface of the anterior eye segment [in Russian]. Vestn Oftalmol. 2001;117(3):45-47.
PUBMED
9. Kobayashi A, Shirao Y, Yoshita T; et al. Temporary amniotic membrane patching for acute chemical burns. Eye. 2003;17(2):149-158.
FULL TEXT
|
ISI
| PUBMED
10. Poonyathalang A, Preechawat P, Pomsathit J, Mahaisaviriya P. Reconstruction of contracted eye socket with amniotic membrane graft. Ophthal Plast Reconstr Surg. 2005;21(5):359-362.
FULL TEXT
|
ISI
| PUBMED
11. Muraine M, Gueudry J, Toubeau D; et al. Advantages of amniotic membrane transplantation in eye surface diseases [in French]. J Fr Ophtalmol. 2006;29(9):1070-1083.
FULL TEXT
|
ISI
| PUBMED
12. Finger PT, Reddy S, Chin K. High-frequency ultrasound characteristics of 24 iris and iridociliary melanomas: before and after plaque brachytherapy. Arch Ophthalmol. 2007;125(8):1051-1058.
FREE FULL TEXT
13. Yoshita T, Kobayashi A, Takahashi M, Sugiyama K. Reliability of intraocular pressure by Tono-Pen XL over amniotic membrane patch in human. J Glaucoma. 2004;13(5):413-416.
FULL TEXT
|
ISI
| PUBMED
14. Finger PT. Tumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol. 2000;84(9):1068-1070.
FREE FULL TEXT
15. Finger PT, Lu D, Buffa A, DeBlasio DS, Bosworth JL. Palladium-103 versus iodine-125 for ophthalmic plaque radiotherapy. Int J Radiat Oncol Biol Phys. 1993;27(4):849-854.
ISI
| PUBMED
16. Haik B, Ainbinder DJ, Finger PT; et al. Part X: ophthalmic sites: carcinoma of the eyelid, carcinoma of the conjunctiva, malignant melanoma of the conjunctiva, malignant melanoma of the uvea, retinoblastoma, carcinoma of the lacrimal gland, sarcoma of the orbit. In: Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002:347-384.17. Geisse LJ, Robertson DM. Iris melanomas. Am J Ophthalmol. 1985;99(6):638-648.
ISI
| PUBMED
18. Harbour JW, Augsburger JJ, Eagle RC Jr. Initial management and follow-up of melanocytic iris tumors. Ophthalmology. 1995;102(12):1987-1993.
ISI
| PUBMED
19. Memmen JE, McLean IW. The long-term outcome of patients undergoing iridocyclectomy. Ophthalmology. 1990;97(4):429-432.
ISI
| PUBMED
20. Lumbroso-Le Rouic L, Charif Chefchaouni M, Levy C; et al. 125I plaque brachytherapy for anterior uveal melanomas. Eye. 2004;18(9):911-916.
FULL TEXT
|
ISI
| PUBMED
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
